한글목차

세계의 수포성 표피 박리증 치료제 시장은 2030년까지 81억 달러에 달할 전망

2023년에 41억 달러로 추정되는 세계의 수포성 표피 박리증 치료제 시장은 분석 기간인 2023-2030년에 CAGR 10.2%로 성장하며, 2030년에는 81억 달러에 달할 것으로 예측됩니다. 본 리포트에서 분석한 부문의 하나인 항생제는 CAGR 9.3%를 기록하며, 분석 기간 종료시에는 40억 달러에 달할 것으로 예상됩니다. 진통제 부문의 성장률은 분석 기간 중 CAGR 10.3%로 추정됩니다.

미국 시장은 11억 달러로 추정, 중국은 CAGR 8.6%로 성장 예측

미국의 수포성 표피 박리증 치료제 시장은 2023년에 11억 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 2030년까지 12억 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2023-2030년의 CAGR은 8.6%입니다. 기타 주목해야 할 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 7.9%와 9.7%로 예측됩니다. 유럽에서는 독일이 CAGR 4.2%로 성장할 것으로 예측됩니다.

세계의 수포성 표피 박리증 치료제 시장 - 주요 동향과 촉진요인 정리

수포성 표피 박리증(EB)은 희귀한 유전성 결합조직 질환으로, 피부가 매우 약해져 사소한 마찰이나 외상에도 쉽게 물집이 생기고 찢어지며, EB의 중증도는 다양하며, 일부는 생명을 위협할 수도 있습니다. 현재 치료법은 주로 증상 관리와 감염 및 만성 상처와 같은 합병증 예방에 초점을 맞추었습니다. 기존 치료법에는 상처 관리, 통증 관리, 영양 지원, 감염 대책 등이 있습니다. 그러나 최근 유전자 치료, 단백질 대체 요법, 줄기세포 치료 등의 발전은 보다 효과적이고 표적화된 치료를 위한 유망한 새로운 길을 제공합니다. 연구자들과 제약회사들은 EB의 근본적인 유전적 원인을 해결하기 위해 이러한 혁신적인 접근법을 적극적으로 모색하고 있으며, 환자들의 삶의 질을 크게 향상시키는 것을 목표로 하고 있습니다.

수포성 표피 박리증 치료제 시장은 기술 발전과 질병의 유전적 기반에 대한 더 깊은 이해에 힘입어 괄목할 만한 발전을 거듭하고 있습니다. 큰 흐름 중 하나는 EB를 유발하는 유전자 돌연변이를 교정할 수 있는 가능성을 보여준 CRISPR-Cas9와 같은 유전자 편집 기술에 대한 관심이 높아지고 있다는 점입니다. 또한 EB 환자의 결손 또는 기능 장애가 있는 단백질을 회복시키는 것을 목표로 하는 단백질 보충 요법도 지지받고 있습니다. 줄기세포 치료는 또 다른 유망한 분야로, 건강한 피부 조직을 재생하기 위해 줄기세포를 사용하는 임상시험이 진행되고 있습니다. 또한 환자 개개인의 특정 유전자 변이 및 특징에 따라 치료하는 맞춤형 의료에 대한 관심도 높아지고 있습니다. 이러한 접근 방식은 치료 효과를 높일 뿐만 아니라 잠재적인 부작용을 최소화할 수 있습니다.

수포성 표피 박리증 치료제 시장의 성장은 몇 가지 요인에 의해 주도되고 있습니다. 유전자 치료, 단백질 대체 요법, 줄기세포 치료의 기술 발전은 EB에 사용할 수 있는 치료 옵션을 확대하여 시장 성장을 가속하고 있습니다. 또한 EB 유병률 증가는 인식 개선 및 조기 진단과 함께 효과적인 치료법에 대한 수요 증가에 기여하고 있습니다. 또한 제약회사와 학계의 연구개발에 대한 막대한 투자는 기술 혁신을 촉진하고 새로운 치료법 개발을 가속화하고 있습니다. 희귀질환 치료제 지정 및 신속 승인과 같은 규제적 지원도 EB 치료제 개발을 촉진하고 있습니다. 또한 맞춤형 의료 접근법의 채택이 증가함에 따라 표적화된 맞춤형 치료에 대한 수요가 증가하고 있습니다. 마지막으로 환자 지원 단체와 공중보건 노력은 인지도를 높이고 새로운 치료법의 채택을 촉진하는 데 중요한 역할을 하고 있으며, 이는 궁극적으로 시장 확대에 기여하고 있습니다.

조사 대상 기업의 예(주목 86사)

• Abeona Therapeutics
• Aegle Therapeutics
• Alphyn Biologics
• Castle Creek Biosciences, Inc.
• Chiesi Global Rare Disease
• Eloxx Pharmaceuticals Inc
• Holostem Terapie Avanzate Srl
• InMed Pharmaceuticals Inc.
• Krystal Biotech
• Prime Therapeutics
• Quoin Pharmaceuticals
• RegeneRx Biopharmaceuticals, Inc.
• RHEACELL
• Shionogi & Co., Ltd.
• TWI Biotechnology, Inc.

목차

제1장 조사 방법

제2장 개요

• 시장 개요
• 주요 기업
• 시장 동향과 촉진요인
• 세계 시장의 전망

제3장 시장 분석

• 미국
• 캐나다
• 일본
• 중국
• 유럽
• 프랑스
• 독일
• 이탈리아
• 영국
• 기타 유럽
• 아시아태평양
• 기타 지역

제4장 경쟁

영문목차

Global Epidermolysis Bullosa Therapeutics Market to Reach US$8.1 Billion by 2030

The global market for Epidermolysis Bullosa Therapeutics estimated at US$4.1 Billion in the year 2023, is expected to reach US$8.1 Billion by 2030, growing at a CAGR of 10.2% over the analysis period 2023-2030. Antibiotics, one of the segments analyzed in the report, is expected to record a 9.3% CAGR and reach US$4.0 Billion by the end of the analysis period. Growth in the Analgesics segment is estimated at 10.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.1 Billion While China is Forecast to Grow at 8.6% CAGR

The Epidermolysis Bullosa Therapeutics market in the U.S. is estimated at US$1.1 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$1.2 Billion by the year 2030 trailing a CAGR of 8.6% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.9% and 9.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.2% CAGR.

Global Epidermolysis Bullosa Therapeutics Market - Key Trends and Drivers Summarized

Epidermolysis Bullosa (EB) is a rare, inherited connective tissue disorder that results in the skin being extremely fragile and prone to blistering and tearing from minor friction or trauma. The severity of EB can vary widely, with some forms being life-threatening. Current therapeutic approaches primarily focus on managing symptoms and preventing complications, such as infections and chronic wounds. Traditional treatments include wound care, pain management, nutritional support, and infection control. However, recent advancements in gene therapy, protein replacement therapy, and stem cell therapy offer promising new avenues for more effective and targeted treatments. Researchers and pharmaceutical companies are actively exploring these innovative approaches to address the underlying genetic causes of EB, aiming to improve the quality of life for patients significantly.

The market for Epidermolysis Bullosa therapeutics has been witnessing significant developments driven by technological advancements and a deeper understanding of the disease's genetic basis. One of the major trends is the increasing focus on gene editing technologies, such as CRISPR-Cas9, which have shown potential in correcting genetic mutations responsible for EB. Additionally, protein replacement therapies, which aim to restore the missing or dysfunctional proteins in EB patients, are also gaining traction. Stem cell therapy represents another promising frontier, with clinical trials exploring the use of stem cells to regenerate healthy skin tissue. Furthermore, there is a growing trend towards personalized medicine, where treatments are tailored to the specific genetic mutations and characteristics of individual patients. This approach not only enhances treatment efficacy but also minimizes potential side effects.

The growth in the Epidermolysis Bullosa therapeutics market is driven by several factors. Technological advancements in gene therapy, protein replacement therapy, and stem cell therapy are expanding the treatment options available for EB, thereby driving market growth. The rising prevalence of EB, coupled with increased awareness and early diagnosis, is also contributing to the growing demand for effective therapies. Additionally, substantial investments in research and development by pharmaceutical companies and academic institutions are fostering innovation and accelerating the development of new treatments. Regulatory support, including orphan drug designations and fast-track approvals, is encouraging the development of EB therapies. Furthermore, the increasing adoption of personalized medicine approaches is generating demand for targeted and individualized treatments. Lastly, patient advocacy groups and public health initiatives are playing a crucial role in raising awareness and driving the adoption of new therapies, ultimately contributing to the market's expansion.

Select Competitors (Total 86 Featured) -

• Abeona Therapeutics
• Aegle Therapeutics
• Alphyn Biologics
• Castle Creek Biosciences, Inc.
• Chiesi Global Rare Disease
• Eloxx Pharmaceuticals Inc
• Holostem Terapie Avanzate Srl
• InMed Pharmaceuticals Inc.
• Krystal Biotech
• Prime Therapeutics
• Quoin Pharmaceuticals
• RegeneRx Biopharmaceuticals, Inc.
• RHEACELL
• Shionogi & Co., Ltd.
• TWI Biotechnology, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Global Economic Update
  • Epidermolysis Bullosa Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Prevalence of Epidermolysis Bullosa Expands Addressable Market Opportunity
  • Advancements in Gene Therapy Propel Growth in Epidermolysis Bullosa Therapeutics Market
  • Innovative Protein Replacement Therapies Strengthen Business Case for EB Treatments
  • Stem Cell Therapy Developments Accelerate Demand for Novel EB Therapeutics
  • Increasing Awareness and Early Diagnosis Spur Growth in EB Therapeutics Market
  • Integration of Digital Health Technologies Throws the Spotlight on EB Treatment Advancements
  • Growing Use of CRISPR-Cas9 Technology Expands Addressable Market for EB Treatments
  • Emerging Combination Therapies Propel Growth in Epidermolysis Bullosa Market
  • Economic Burden of EB on Patients and Healthcare Systems Drives Demand for Cost-Effective Therapies
  • Increasing Healthcare Expenditure Accelerates Demand for Epidermolysis Bullosa Treatments
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Epidermolysis Bullosa Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Epidermolysis Bullosa Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Epidermolysis Bullosa Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 4: World 16-Year Perspective for Epidermolysis Bullosa Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 7: World 16-Year Perspective for Antibiotics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Analgesics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Analgesics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 10: World 16-Year Perspective for Analgesics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Other Product Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Other Product Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 13: World 16-Year Perspective for Other Product Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Epidermolysis Bullosa Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • TABLE 14: USA Recent Past, Current & Future Analysis for Epidermolysis Bullosa Therapeutics by Product Type - Antibiotics, Analgesics and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 15: USA Historic Review for Epidermolysis Bullosa Therapeutics by Product Type - Antibiotics, Analgesics and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 16: USA 16-Year Perspective for Epidermolysis Bullosa Therapeutics by Product Type - Percentage Breakdown of Value Sales for Antibiotics, Analgesics and Other Product Types for the Years 2014, 2024 & 2030
• CANADA
  • TABLE 17: Canada Recent Past, Current & Future Analysis for Epidermolysis Bullosa Therapeutics by Product Type - Antibiotics, Analgesics and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 18: Canada Historic Review for Epidermolysis Bullosa Therapeutics by Product Type - Antibiotics, Analgesics and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 19: Canada 16-Year Perspective for Epidermolysis Bullosa Therapeutics by Product Type - Percentage Breakdown of Value Sales for Antibiotics, Analgesics and Other Product Types for the Years 2014, 2024 & 2030
• JAPAN
  • Epidermolysis Bullosa Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • TABLE 20: Japan Recent Past, Current & Future Analysis for Epidermolysis Bullosa Therapeutics by Product Type - Antibiotics, Analgesics and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 21: Japan Historic Review for Epidermolysis Bullosa Therapeutics by Product Type - Antibiotics, Analgesics and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 22: Japan 16-Year Perspective for Epidermolysis Bullosa Therapeutics by Product Type - Percentage Breakdown of Value Sales for Antibiotics, Analgesics and Other Product Types for the Years 2014, 2024 & 2030
• CHINA
  • Epidermolysis Bullosa Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • TABLE 23: China Recent Past, Current & Future Analysis for Epidermolysis Bullosa Therapeutics by Product Type - Antibiotics, Analgesics and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 24: China Historic Review for Epidermolysis Bullosa Therapeutics by Product Type - Antibiotics, Analgesics and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 25: China 16-Year Perspective for Epidermolysis Bullosa Therapeutics by Product Type - Percentage Breakdown of Value Sales for Antibiotics, Analgesics and Other Product Types for the Years 2014, 2024 & 2030
• EUROPE
  • Epidermolysis Bullosa Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • TABLE 26: Europe Recent Past, Current & Future Analysis for Epidermolysis Bullosa Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • TABLE 27: Europe Historic Review for Epidermolysis Bullosa Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 28: Europe 16-Year Perspective for Epidermolysis Bullosa Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
  • TABLE 29: Europe Recent Past, Current & Future Analysis for Epidermolysis Bullosa Therapeutics by Product Type - Antibiotics, Analgesics and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 30: Europe Historic Review for Epidermolysis Bullosa Therapeutics by Product Type - Antibiotics, Analgesics and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 31: Europe 16-Year Perspective for Epidermolysis Bullosa Therapeutics by Product Type - Percentage Breakdown of Value Sales for Antibiotics, Analgesics and Other Product Types for the Years 2014, 2024 & 2030
• FRANCE
  • Epidermolysis Bullosa Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • TABLE 32: France Recent Past, Current & Future Analysis for Epidermolysis Bullosa Therapeutics by Product Type - Antibiotics, Analgesics and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 33: France Historic Review for Epidermolysis Bullosa Therapeutics by Product Type - Antibiotics, Analgesics and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 34: France 16-Year Perspective for Epidermolysis Bullosa Therapeutics by Product Type - Percentage Breakdown of Value Sales for Antibiotics, Analgesics and Other Product Types for the Years 2014, 2024 & 2030
• GERMANY
  • Epidermolysis Bullosa Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • TABLE 35: Germany Recent Past, Current & Future Analysis for Epidermolysis Bullosa Therapeutics by Product Type - Antibiotics, Analgesics and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 36: Germany Historic Review for Epidermolysis Bullosa Therapeutics by Product Type - Antibiotics, Analgesics and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 37: Germany 16-Year Perspective for Epidermolysis Bullosa Therapeutics by Product Type - Percentage Breakdown of Value Sales for Antibiotics, Analgesics and Other Product Types for the Years 2014, 2024 & 2030
• ITALY
  • TABLE 38: Italy Recent Past, Current & Future Analysis for Epidermolysis Bullosa Therapeutics by Product Type - Antibiotics, Analgesics and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 39: Italy Historic Review for Epidermolysis Bullosa Therapeutics by Product Type - Antibiotics, Analgesics and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 40: Italy 16-Year Perspective for Epidermolysis Bullosa Therapeutics by Product Type - Percentage Breakdown of Value Sales for Antibiotics, Analgesics and Other Product Types for the Years 2014, 2024 & 2030
• UNITED KINGDOM
  • Epidermolysis Bullosa Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • TABLE 41: UK Recent Past, Current & Future Analysis for Epidermolysis Bullosa Therapeutics by Product Type - Antibiotics, Analgesics and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 42: UK Historic Review for Epidermolysis Bullosa Therapeutics by Product Type - Antibiotics, Analgesics and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 43: UK 16-Year Perspective for Epidermolysis Bullosa Therapeutics by Product Type - Percentage Breakdown of Value Sales for Antibiotics, Analgesics and Other Product Types for the Years 2014, 2024 & 2030
• REST OF EUROPE
  • TABLE 44: Rest of Europe Recent Past, Current & Future Analysis for Epidermolysis Bullosa Therapeutics by Product Type - Antibiotics, Analgesics and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 45: Rest of Europe Historic Review for Epidermolysis Bullosa Therapeutics by Product Type - Antibiotics, Analgesics and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 46: Rest of Europe 16-Year Perspective for Epidermolysis Bullosa Therapeutics by Product Type - Percentage Breakdown of Value Sales for Antibiotics, Analgesics and Other Product Types for the Years 2014, 2024 & 2030
• ASIA-PACIFIC
  • Epidermolysis Bullosa Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • TABLE 47: Asia-Pacific Recent Past, Current & Future Analysis for Epidermolysis Bullosa Therapeutics by Product Type - Antibiotics, Analgesics and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 48: Asia-Pacific Historic Review for Epidermolysis Bullosa Therapeutics by Product Type - Antibiotics, Analgesics and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 49: Asia-Pacific 16-Year Perspective for Epidermolysis Bullosa Therapeutics by Product Type - Percentage Breakdown of Value Sales for Antibiotics, Analgesics and Other Product Types for the Years 2014, 2024 & 2030
• REST OF WORLD
  • TABLE 50: Rest of World Recent Past, Current & Future Analysis for Epidermolysis Bullosa Therapeutics by Product Type - Antibiotics, Analgesics and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • TABLE 51: Rest of World Historic Review for Epidermolysis Bullosa Therapeutics by Product Type - Antibiotics, Analgesics and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • TABLE 52: Rest of World 16-Year Perspective for Epidermolysis Bullosa Therapeutics by Product Type - Percentage Breakdown of Value Sales for Antibiotics, Analgesics and Other Product Types for the Years 2014, 2024 & 2030

IV. COMPETITION